BioLineRx Ltd. Files Form 6-K: Key Updates and Press Release Insights

Here are the key pieces of information extracted from the financial report section provided:

1. Document Type: The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC.
2. Company Information:

• Name: BioLineRx Ltd.
• Address: 2 HaMa’ayan Street, Modi’in 7177871, Israel.

3. Filing Date: This report is dated January 17, 2025.
4. Commission File Number: 001-35223.
5. Report Content: The registrant issued a press release on January 17, 2025, which is attached as Exhibit 1 to this Form 6-K. The first two paragraphs of the attached press release are incorporated by reference into all effective registration statements filed under the Securities Act of 1933.
6. Annual Report Filing: The company indicated that it files annual reports under Form 20-F rather than Form 40-F.
7. Signature: The report was signed by Philip A. Serlin, the Chief Executive Officer of BioLineRx Ltd.
8. Importance of the Filing: This document serves to inform the SEC and investors of significant updates or events related to BioLineRx Ltd. as required under the Securities Exchange Act of 1934.

Overall, the report provides essential information regarding the company's compliance with regulations and updates of interest to stakeholders.